The power and pitfalls of omics part 2: epigenomics, transcriptomics and ME/CFS
Simon McGrath concludes his blog about the remarkable Prof George Davey Smith's smart ideas for understanding diseases, which may soon be applied to ME/CFS.
Discuss the article on the Forums.

Rituximab is not effective for the treatment of fatigue in primary biliary cholangitis

Discussion in 'Rituximab: News and Research' started by jaybee00, Apr 23, 2017.

  1. jaybee00

    jaybee00

    Messages:
    80
    Likes:
    94
  2. ukxmrv

    ukxmrv Senior Member

    Messages:
    4,337
    Likes:
    4,408
    London
    As I vaguely remember it there was a study that was allocated CFS funds into a study similar to this.

    http://www.southampton.ac.uk/news/2013/04/patients-with-chronic-fatigue.page

    Researchers at the launch will be discussing some of the key issues they are facing and the areas that are making progress. They will also be explaining some of their thoughts for future research and their latest preliminary findings. These include, why some patients experience significant pain that is unresponsive to pain killers; whether using a monoclonal antibody (Rituximab), which is highly successful in treating rheumatoid arthritis, some cancers and the profound fatigue experienced in patients with an immune liver disease known as primary biliary cirrhosis, could be used as a test experimental medicine approach in order to understand more about fatigue mechanisms; and the link between blood pressure problems and CFS patients.
     

See more popular forum discussions.

Share This Page